News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.
Galderma shares fell after the Swiss skincare specialist failed to obtain approval from the U.S. Food and Drug Administration for its latest product to rival AbbVie’s Botox for the second time. Shares in Galderma were down 5.6% in European morning trading Wednesday, leaving the stock up 7% since the start of the year. The company said it received a complete response letter from the FDA declining its application for the product—marketed in some countries as Relfydess and also known as relabotulinumtoxinA—with comments related to observations during an inspection of the company’s manufacturing site and its analytical method optimization.
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn't need to conduct additional studies of the drug. - SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO.
AbbVie announced Monday a $10.9 billion plan to acquire immunology-focused Apogee Therapeutics, sending Apogee stock flying.
The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis
June 22 (Reuters) - AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline.
AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18, a steep markup ...
(Bloomberg) -- Global stocks are ending a strong week on a cautious note as relief over an interim peace deal between the US and Iran gave way to a focus on the significant hurdles that remain to secure a lasting agreement.Most Read from BloombergRead the 14-Point Draft Memorandum Between the US and IranModi Warns of ‘Shortage of Trust’ Ahead of Trump MeetingTrump Blows Through His Iran Red Lines in Justifying Peace DealUS and Iran Delay Nuclear Talks as Lebanon Clashes WorsenUS Tells ASML It’s
At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched. This article walks through exactly what ... This Is What a $1 Million Dividend Portfolio Pays After Taxes
Glenmark Pharmaceuticals Ltd (BOM:532296) reports robust Q4 growth, achieves debt-free status, and sets ambitious targets for FY27.
Partnership strategy has produced great pharma bargains—and left the company exposed.
Johnson & Johnson seems to have perfected the art of the biotech deal. Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices. A biotech partnership is a bit like an open relationship: Your partner can always fall in love with someone else.
The U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine-pvzy (sold under the brand name Decnupaz), a highly targeted therapy for adults dealing with an ultra-rare and aggressive form of blood cancer.
Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours. It repeats annually, forever, on the same dollars you already earned. This series exists because most readers know what a Roth IRA is ... The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)
Q1 earnings show this Dividend King still looks built for the long term.